We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01950637
First Posted: September 25, 2013
Last Update Posted: January 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novo Nordisk A/S
September 23, 2013
September 25, 2013
January 13, 2017
January 2012
January 2013   (Final data collection date for primary outcome measure)
  • Basal insulin dosing irregularities: frequency of missed doses, mistimed doses, or reduced doses (patient questionnaire) [ Time Frame: In the past 30 days prior to the day when responding to the online questionnaire ]
  • Level of patient dosing irregularity: missed, mistimed and reduced dose (HCP questionnaire) [ Time Frame: Day 1 (when responding to the online questionnaire) ]
Same as current
Complete list of historical versions of study NCT01950637 on ClinicalTrials.gov Archive Site
  • Incidence of intentional dosing irregularities and reasons for this behaviour [ Time Frame: Day 1 (when responding to the online questionnaire) ]
  • Impact of dosing irregularity on functional well-being [ Time Frame: Day 1 (when responding to the online questionnaire) ]
  • Frequency of self-treated hypoglycaemia [ Time Frame: In the past 30 days prior to the day when responding to the online questionnaire ]
Same as current
Not Provided
Not Provided
 
GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus
GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus
This study is conducted Asia, Europe and North America. The aim of this study is to describe insulin therapy adherence and the burden of non-adherence on patient functioning, well-being and diabetes management.
Not Provided
Observational
Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample
Insulin treated patients with type 2 diabetes, and HCPs involved in the treatment, management of diabetes and care of patients with type 2 diabetes.
  • Diabetes
  • Diabetes Mellitus, Type 2
  • Behavioral: No treatment given
    Completion of 90-item online questionnaire.
  • Behavioral: survey
    Completion of 58-item online questionnarie.
  • Patients with type 2 diabetes mellitus (T2DM)
    Intervention: Behavioral: No treatment given
  • Healthcare professionals (HCPs)
    Intervention: Behavioral: survey

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4000
January 2013
January 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • PATIENTS WITH T2DM:
  • Diagnosed with type 2 diabetes by a healthcare professional
  • Currently being treated with insulin medication, excluding premix insulin treatment
  • Age at least 40 years
  • Diagnosed as having type 2 diabetes over the age of 40
  • HCPs:
  • Primary care physician, diabetes specialist (diabetologist/endocrinologist) or diabetes specialist nurse/diabetes nurse educator
  • Have a minimum of 2 years experience within current speciality
  • See a minimum of 20 type 2 diabetes patients per month (40 for diabetes specialists), of which at least 10 per month must be on modern (analogue) inulins
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Canada,   Denmark,   Germany,   Japan,   United Kingdom,   United States
 
 
NCT01950637
GAPP2
U1111-1136-2536 ( Other Identifier: WHO )
No
Not Provided
Not Provided
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Novo Nordisk A/S
January 2017